| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 75.1 | 94.8 | 89.1 |
| Other income | 2.0 | 0.2 | 2.3 |
| Total income | 77.2 | 95.0 | 91.5 |
| Profit before exceptional items & tax | 0.9 | 8.8 | 3.9 |
| Profit before tax | 0.9 | 8.8 | 3.9 |
| Net profit | 0.3 | 6.6 | 3.5 |
| Operating margin | 1.2% | 9.3% | 4.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -91.40% |
|---|---|
| Net profit, quarter on quarter | -95.50% |
| Revenue, year on year | -15.70% |
BSE results filing, NSE: HALEOSLABS. Figures extracted from the filing.
Haleos Labs Ltd: key numbers
- Share price
- ₹1,584.00
- Market cap
- ₹478.9 Cr
- Revenue (annual)
- ₹333.8 Cr
- Net profit (annual)
- ₹17.31 Cr
- P/E (TTM)
- 30.3×Sector 47.4×
- Promoter holding
- 72.11%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Haleos Labs Ltd
All →Haleos Labs Business Update
USFDA inspected the material subsidiary Mahi Drugs' API facility in Parawada. The inspection concluded with zero Form 483 observations.
Haleos Labs Other Announcement
Haleos Labs Ltd notified shareholders of the Annual Report and AGM notice weblink, while requesting updates to their KYC and email addresses.
Haleos Labs Annual Report
Haleos Labs Ltd has submitted its Annual Report for the financial year 2025-26, along with the Notice for its 20th Annual General Meeting.
Haleos Labs Dividend
Haleos Labs Limited recommended a final dividend of ₹15 per equity share for FY 2025-26. The record date is fixed for September 23, 2026.
Haleos Labs Annual General Meeting
Haleos Labs Limited announced postal ballot results where shareholders approved director reappointment and related party transactions. However, a resolution for managerial remuneration was rejected by shareholders.
Haleos Labs Management Change
Haleos Labs Limited has re-appointed Dr. Mannam Malakondaiah and Dr. Srinivas Samavedam as Independent Directors for five-year terms starting November 13, 2026. Shareholder approval is required.
- Execution
- 5 years